ABSTRACT
INTRODUCTION
The induction of effector T cell death during immune responses is crucial for preventing the development of immunopathology and for prolonging allograft survival in response to tolerizing regimens or immunosuppressive drugs (1, 2) . Activation-induced cell death (AICD) is one main mechanism of T cell death that occurs in response to T cell receptor (TCR) re-stimulation in activated T cells and prevents the pathological persistence of autoreactive T cells (1) . AICD is mediated by the stimulation of death receptors on the surface of effector T cells that occurs in response to death-inducing ligands present on neighboring cells. This causes the activation of caspase-8 followed by the activation of caspase-3, which ultimately leads to dismantling of the cell. Several death-inducing ligands have been described to be capable of mediating AICD, although FasL-mediated activation of Fas is a main mechanism (3) (4) (5) .
The intrinsic susceptibility of T cells to AICD is regulated by expression of cellular FLICE inhibitory protein (c-FLIP), which is structurally similar to caspase-8 but lacks a C-terminal caspase-like domain (6) . c-FLIP is expressed in activated T cells where it prevents caspase-8 activation in response to FasL and other deathinducing ligands. Long (c-FLIP L ) and short isoforms (c-FLIP S ) of c-FLIP have been reported (6) , and c-FLIP S has been suggested to regulate the susceptibility of activated human T cells to Fasmediated cell death (7) . However, activation of T cells in this mentioned study was conducted by initial stimulation with phytohemagglutinin (PHA) , which provides only TCR stimulation. Physiologically, T cell responses are influenced by the presence of TCR stimulation (signal 1), costimulation (signal 2), and cytokine signals (signal 3). Therefore, the effect of cytokine signals, provided in this context, in determining the susceptibility of human T cells to AICD remains incompletely defined.
Specific biological conditions determine the types of cytokines produced during inflammation and the nature of these inflammatory cytokines dictates the fate of CD8 effector T cell responses. For instance, IL-12 is produced in response to several pathogens and high levels of this cytokine during CD8 T cell activation drives the development of short-lived effector cells characterized by potent effector functions, such as IFNγ production and cytolytic properties. In contrast, the presence of lower levels of IL-12 favors the generation of long-lived memory CD8 T cells (8) . In addition to pathogen infection, ischemic damage also triggers an inflammatory response that clearly affects immune responses in organ transplantation, cardiovascular diseases, stroke, and in response to tumors (9) . IL-1α, IL-1β, and IL-6 are produced rapidly in response to ischemic damage (10) (11) (12) , and IL-23 has recently been shown to be produced following ischemic damage of heart and liver allografts (13) . The combination of IL-1, IL-6, and IL-23 is also involved in the differentiation of CD4 T cells into IL-17A-producing effector cells, termed Th17 cells, which have distinct roles in physiology and pathology (14, 15) . Interestingly, Th17 responses have been linked to ischemic damage in heart transplantation (16) . Further, CD8 T cells have been shown to be recruited into cardiac allografts at very early time-points after transplantation that are associated with ischemic damage (17) . Because CD8 T cells are exposed to the combination of IL-1, IL-6, and IL-23 during inflammatory conditions, understanding the effects of these cytokines on CD8 T cell biology provides important insight into the regulation of adaptive immune responses.
We have examined previously the effects of soluble mediators of inflammation, such as nitric oxide, on human CD8 T cell death (18, 19) . In the current study, we have examined the effects of inflammatory cytokines on determining the susceptibility of human CD8 T cells to postactivation cell death.
We have focused specifically on the response of human T cells because there are some distinctions between the mechanisms by which inflammatory cytokines affect the biology of human as compared to mouse effector T cells (20) . Activated CD8 T cells express IL-12Rβ1 and IL-12Rβ2 (21) . In addition, CD8 T cells respond to IL-1 stimulation, express IL-6R and gp130 in resting conditions, and some express IL-23R after activation (22) (23) (24) (25) . Thus, we examined the effects of IL-12 as well as the combination of IL-1, IL-6, and IL-23 (IL-1/6/23) on post-activation cell death of human CD8 T cells. Human CD8 T cells activated in the presence of IL-12 underwent a progressive increase in cell death after TCR stimulation, but CD8 T cells activated in IL-1/6/23 did not. In fact, IL-1/6/23 inhibited cell death of CD8 T cells activated in IL-12. Reduced cell death of human CD8 T cells activated in IL-1/6/23 was due to resistance to Fas-mediated AICD, which was a result of a low level of FasL expression and expression of c-FLIP S . Finally, IL-1 or IL-6 alone was sufficient to inhibit cell death of CD8 T cells activated in IL-12 while the effects of IL-23 were variable.
All together, our findings provide important insight into the effects of inflammatory signals in determining the persistence of human CD8 effector T cells during immune responses.
EXPERIMENTAL PROCEDURES

Human Cell Isolation and Culture
Human peripheral blood cells were obtained by phlebotomy of healthy volunteers with approval of the appropriate Institutional Review Boards. Mononuclear cells were isolated from peripheral blood by density gradient centrifugation, and CD8 T cells purified to >98% purity by positive isolation with Dynal magnetic beads (Invitrogen, Carlsbad, CA) as described (18) .
In some experiments, purified T cells were stained with a PE-conjugated CD45RO antibody (BD Biosciences, Franklin Lakes, NJ) before cell sorting using a BD FACS Aria.
CD8 T cells were stimulated with plate-bound anti-CD3 (3 µg; eBioscience, San Diego, CA) and soluble anti-CD28 (1 µg/mL; eBioscience) in RPMI + 10% FCS as described (19) . Cells were treated with IL-12 (10 ng/mL; R&D Systems, Minneapolis, MN), or IL-1α (10 ng/mL; NCI Biological Resources Branch Preclinical Repository), IL-6 (50 ng/mL; Peprotech, Rocky Hill, NJ), and/or IL-23 (50 ng/mL; R&D Systems). A neutralizing antibody to IFNγ (10 µg/mL; BD Biosciences) was also added in some experiments. In certain experiments, a FasL neutralizing antibody (10 μg/mL; BD Biosciences) was added, a caspase-8 inhibitor z-IETD.fmk (EMD Chemicals, Gibbstown, NJ) added on day 3 and 5 post-stimulation (25 µM on each day), or an agonistic Fas antibody (10 μM; clone CH11; Millipore, Billerica, MA) added at day 4 poststimulation.
In co-culture experiments, CD8 T cells were activated in the presence of either IL-12 or IL-1/6/23 for four days, and then harvested and washed. CD8 T cells activated in IL-1/6/23 were CFSE labelled (0.5 μM; Invitrogen) as described (18) and those activated in IL-12 were not. CFSElabelled CD8 T cells that had been activated in IL-1/6/23 were then co-cultured at a 1:1 ratio with unlabelled CD8 T cells that had been activated in IL-12. Anti-CD3 and anti-CD28 stimulation was maintained in these co-cultures.
Quantification of Cell Death and Viability
Cell death was measured by staining cells with propidium iodide (PI; Invitrogen) as described previously (19) . We were not able to evaluate phosphatidylserine exposure in addition to membrane permeabilization in our experiments because activation of human CD8 T cells induces transient exposure of this lipid on the outer membrane that is unrelated to cell death, thereby confounding the interpretation of data obtained by this method [data not shown and (26)]. Total cell viability was quantified with a MTS assay (Promega, Madison, WI) as described (19) .
AICD was induced using conditions described previously (19, 27) . Specifically, human CD8 T cells were stimulated in IL-12 or IL-1/6/23 for three days, removed from stimulation, washed extensively, and cultured in IL-2 (50 U/mL; NCI) for at least five days. T cells were then either left unstimulated or were re-stimulated with platebound anti-CD3 (3 µg) for 16h and cell death measured by PI staining.
Flow Cytometry
Flow cytometry was performed as described previously (18) . In some experiments, CD8 T cells were CFSE labeled prior to stimulation. Fas and FasL surface protein expression was examined by staining cells with a PE-conjugated antibody to Fas (BD Biosciences) or a biotin-labelled antibody to FasL (BD Biosciences) followed by PEconjugated streptavidin. All data was acquired on a BD FACS Aria.
Analysis of RNA Expression and Cytokine Secretion
Total RNA was isolated using a RNA Minikit (Qiagen, Valencia, CA) and Taqman quantitative RT-PCR (RT-qPCR) performed as described (18) using validated primer/probe sets (Applied Biosystems, Foster City, CA). Data was acquired on an ABI 7900HT iCycler. IFNγ levels were quantified using an ELISA kit (Invitrogen).
Cell Lysis and Western Blotting
CD8 T cells were lysed and Western blotting performed as described (19) using c-FLIP (Upstate, Lake Placid, NY) and β-actin (Sigma) antibodies.
siRNA Knockdown 5 x 10 6 primary resting human CD8 T cells were transfected with 200 pmol of siRNA that targets all isoforms of c-FLIP (Qiagen) or a scrambled control sequence (Qiagen) by amaxa nucleofection using program U-014. Transfected CD8 T cells were rested for 6 h prior to activation.
Statistical Analysis
A two-tailed t-test was performed to determine significant differences between groups. An α-value of <0.05 was determined to be significant.
RESULTS
Human CD8 T cells activated in IL-1/6/23 undergo less AICD than those activated in IL-12
To begin examining the effects of inflammatory cytokines on CD8 T cell death, primary human CD8 T cells were stimulated with plate-bound anti-CD3 and soluble anti-CD28 in the presence of IL-12 or IL-1/6/23, and cell death examined by PI staining at various time-points after activation. There was no difference in the background level of cell death of CD8 T cells activated in the two conditions at early time-points up to day 3 post-stimulation (data not shown). Starting after day 3, there was a progressive increase in cell death of CD8 T cells activated in IL-12 that continued until day 6. In contrast, cell death did not increase in CD8 T cells activated in the presence of IL-1/6/23 at any time point ( Fig. 1C) . Some reports have suggested that certain forms of cell death that occur after TCR stimulation can be mediated by IFNγ (28, 29) . There was more production of IFNγ by human CD8 T cells after activation in the presence of IL-12 as compared to IL-1/6/23 (Supplemental Figure  1) . However, neutralization of IFNγ did not affect cell death in our experiments (Fig. 1D) . Finally, we also evaluated the effects of IL-12 and IL-1/6/23 on cell death of human naïve and memory CD8 T cells after activation. A similar pattern of cell death was observed when purified CD45RO-or CD45RO+ human CD8 T cells were activated in the two conditions (Fig. 1E) . Therefore, human CD8 T cells undergo less cell death and accumulate to a greater extent after activation in IL-1/6/23 as compared to IL-12 and this process is independent of the different levels of IFNγ produced in the two conditions.
Because the cell death we observed occurs in the presence of continued availability of TCR stimulation, we examined the effects of IL-12 and IL-1/6/23 on the susceptibility of human CD8 T cells to AICD. Proliferation was observed in almost all T cells at day 6 after activation and there was no difference in the proportion of CD8 T cells that had undergone proliferation after activation in IL-12 as compared to IL-1/6/23 (82.8 ± 1.4% of cells were CFSE Low after activation in IL-12 as compared to 77.5 ± 4.9% of cells after activation in IL-1/6/23; n=4; p = NS). However, the proportion of proliferated cells that were undergoing cell death was significantly lower in CD8 T cells that had been activated in the presence of IL-1/6/23 as compared to IL-12 ( Fig.  2A and B) . The effect of cytokines on AICD was then examined using a well-established in vitro model (27) . CD8 T cells that were initially activated in IL-1/6/23 underwent significantly less cell death induced by TCR re-stimulation as compared to those activated in IL-12, indicating that they were less susceptible to AICD (Fig. 2C) .
Human CD8 T cells activated in IL-1/6/23 undergo less Fas-mediated cell death than those activated in IL- 12 We then determined the role of the Fas pathway in cell death of CD8 T cells by inhibiting FasL activity with a neutralizing antibody or preventing caspase-8 activity with a pharmacological caspase-8 inhibitor (z-IETD.fmk).
FasL neutralization significantly inhibited cell death of CD8 T cells activated in IL-12 but had no effect on CD8 T cells activated in IL-1/6/23 (Fig. 3A) .
Similar findings were obtained when caspase-8 was inhibited (Fig. 3B) , although greater inhibition was observed with FasL neutralization which is likely due to reduced stability of the caspase-8 inhibitor in aqueous solution over days 3-6 in the experiments. Analysis of Fas, FasL, and c-FLIP expression indicated that human CD8 T cells activated in IL-1/6/23 expressed similar levels of Fas, lower levels of FasL and higher levels of c-FLIP S as compared to cells activated in IL-12 ( Fig. 3C-D) .
The findings above indicate that IL-1/6/23 attenuates Fas-mediated AICD in human CD8 T cells and that this is potentially due to a lower level of FasL expression and/or a higher level of c-FLIP S expression as compared to IL-12. To examine this, we determined the intrinsic susceptibility of human CD8 T cells activated in IL-12 or IL-1/6/23 to Fas-induced cell death by adding an agonistic Fas antibody. This bypasses the requirement for endogenous FasL expression to induce cell death and would be expected to induce the same amount of cell death in both conditions if reduced FasL expression was solely responsible for the attenuated induction of AICD observed in the presence of IL-1/6/23. The concentration of Fas-agonistic antibody used was 10 fold higher than the concentration of antibody needed to induce maximal cell death in Jurkat cells (data not shown). Fas-induced cell death of CD8 T cells activated in IL-1/6/23 was significantly lower than that of cells activated in IL-12 (Fig.  4A) . Therefore, although CD8 T cells activated in IL-1/6/23 express less FasL than those activated in IL-12, replacement of saturating levels of Fas stimulation still results in a lower level of cell death. This suggests that CD8 T cells activated in the presence of IL-1/6/23 are intrinsically resistant to this form of cell death.
To determine further whether CD8 T cells activated in IL-1/6/23 were intrinsically less sensitive to Fas-mediated cell death as compared to those activated in IL-12, the nature of the extrinsic signals was normalized by co-culturing T cells that had been activated in IL-12 with those that had been activated in IL-1/6/23. In these experiments, T cells were activated in IL-12 or IL-1/6/23 for four days. Cells were then harvested and those activated in the presence of IL-1/6/23 were labelled with CFSE prior to being cocultured at a 1:1 ratio with unlabelled CD8 T cells that had been activated in IL-12. Cell death in the CFSE-positive cells (eg. those originally activated in IL-1/6/23) and CFSE-negative cells (eg. those originally activated in IL-12) was determined after two days in co-culture. CD8 T cells originally activated in IL-1/6/23 underwent significantly less cell death in these co-cultures as compared to those originally activated in IL-12 (Fig. 4B,  Supplemental Figure 2) , thereby establishing that CD8 T cells activated in IL-1/6/23 are intrinsically resistant to Fas-induced AICD.
Inhibition of c-FLIP expression increases postactivation cell death of CD8 T cells activated in both cytokine conditions
The role of c-FLIP expression in regulating post-activation cell death of human CD8 T cells activated in IL-12 and in IL-1/6/23 was then examined by inhibiting c-FLIP expression using siRNA gene silencing. In CD8 T cells transfected with non-specific control RNA, total c-FLIP mRNA levels and c-FLIP S protein levels were higher after activation in IL-1/6/23 as compared to activation in IL-12 for five days. Transfection of CD8 T cells with c-FLIP siRNA consistently inhibited expression of this anti-apoptotic molecule to similar levels in both cytokine conditions ( Fig. 5A and B) . Inhibition of c-FLIP expression increased cell death of CD8 T cells activated in both cytokine conditions. However, the amount of cell death in CD8 T cells activated in IL-1/6/23 after inhibition of c-FLIP expression remained slightly lower than those activated in IL-12 that also received c-FLIP siRNA (Fig. 5C) .
Because there is differential expression of FasL on the surface of CD8 T cells activated in IL-12 as compared to IL-1/6/23, we determined whether inhibition of c-FLIP expression normalized the instrinsic susceptibility of CD8 T cells activated in these cytokine conditions to cell death by using the co-culture system. CD8 T cells were transfected with control or c-FLIP siRNA prior to being activated in the presence of IL-12 or IL-1/6/23 for four days. The cells that were activated in the presence of IL-1/6/23 were then CFSE-labelled and co-cultured with corresponding control or c-FLIP siRNA transfected CD8 T cells that had been activated in the presence of IL-12 and were not CFSE-labelled. Cell death in these experiments was measured after one day in coculture because the induction of cell death was accelerated after inhibition of c-FLIP expression and the advanced stage of cell death in cells receiving c-FLIP siRNA after 48h in these cocultures resulted in technical difficulties in accurately quantifying PI-positivity in the CFSElabelled population (data not shown). In cocultures of CD8 T cells receiving control RNA, cells originally activated in IL-1/6/23 underwent signficiantly less cell death than those originally activated in the presence of IL-12. However, in co-cultures of CD8 T cells receiving c-FLIP siRNA, there was no difference in cell death of cells that had been activated in IL-1/6/23 as compared to IL-12 (Fig. 5D ). Taken together, these findings indicate that the higher level of c-FLIP S expression in human CD8 T cells activated in IL-1/6/23 accounts for the intrinsic resistance of these cells to Fas-mediated AICD but that lower levels of FasL expression dictated by IL-1/6/23 can result in less induction of Fas-mediated cell death.
IL-1 or IL-6 is sufficient to inhibit AICD of human CD8 T cells
We then examined the specific cytokines that determine the susceptibility of human CD8 T cells to post-activation cell death. The lower level of cell death in CD8 T cells activated in the presence of IL-1/6/23 could be due to the absence of IL-12, which appears to direct human CD8 T cells to cell death late after activation, or could involve active inhibition of cell death. In order to determine whether IL-1/6/23 is able to actively inhibit postactivation cell death, we examined the effects of IL-12 plus IL-1/6/23 on human CD8 T cell death. CD8 T cells activated in the presence of IL-12 underwent more cell death than those activated in the absence of exogenous cytokines, confirming that IL-12 increases the susceptibility of human CD8 T cells to AICD. Human CD8 T cells activated in IL-12 plus IL-1/6/23 underwent significantly less cell death than those activated in IL-12 and the amount of cell death was quantitatively similar to that of CD8 T cells activated in IL-1/6/23, indicating that IL-1/6/23 is able to actively inhibit AICD (Fig. 6A) .
The effects of IL-1, IL-6, or IL-23 alone on cell death of human CD8 T cells activated in the presence of IL-12 was then examined. IL-1 or IL-6 alone was capable of significantly inhibiting cell death of CD8 T cells that occurs in the presence of IL-12. Although there was less cell death on average of CD8 T cells activated in IL-12 plus IL-23 as compared to IL-12 alone, this did not reach statistical significance which may be due to a large amount of donor variability. Combinations of any two cytokines together did not inhibit cell death to a greater extent than IL-1 or IL-6 alone (Fig. 6A) . Finally, we examined the effects of IL-1 and IL-6 on FasL and c-FLIP expression. IL-1 inhibited the expression of FasL on the surface of CD8 T cells that were activated in the presence of IL-12 but IL-6 did not (Fig. 6B) . In contrast, IL-6 alone increased the expression of c-FLIP S in CD8 T cells activated in the presence of IL-12 but IL-1 did not (Fig. 6C) . These findings indicate that IL-1 and IL-6 attenuate Fas-mediated AICD through distinct mechanisms, namely the attenuation of FasL expression and induction of c-FLIP S expression, respectively. (37) . We are currently examining the specific signaling pathways by which IL-6 regulates c-FLIP expression in human T cells.
We have mostly evaluated the effects of cytokine combinations on CD8 T cell death in our experiments because T cells are likely to be exposed to multiple cytokines during inflammation. This is exemplified by the observed concurrent expression of IL-1 and IL-6 in response to ischemic damage early after organ transplantation (12) . However, IL-1 or IL-6 alone was sufficient to reduce the susceptibility of human CD8 T cells to AICD in response to IL-12, indicating that these cytokines may act in a overlapping manner to control this aspect of CD8 T cell responses. In addition to examining the role of specific cytokines, the majority of our experiments were performed with unseparated CD8 T cells. Recent findings showing that cytokines act on all lymphocytes within reactive lymph nodes during active immune responses indicates that inflammatory cytokines produced by antigen-presenting cells are likely to affect the function of all reactive T cells (38) . We have performed some experiments with isolated naïve and memory CD8 T cells, as determined by CD45RO expression, and determined that IL-12 and IL-1/6/23 similarly affect the susceptibility of CD45RO-and CD45RO+ human CD8 T cells to post-activation cell death.
The expression of c-FLIP may dictate the pathological nature of human T cells as its expression is increased in T cells from patients with multiple sclerosis (MS) and Crohn's disease (39, 40) . Further, the effects of IL-1 and IL-6 on the resistance of human CD8 T cells to Fasmediated AICD may augment the pathological nature of this cell type in autoimmune diseases and organ transplantation (41, 42) .
Indeed, polymorphisms in IL-1RA are associated with susceptibility to MS (43) and IL-1 blockade prolongs allograft survival in mice (44) . IL-6 is increased in plasma of patients with MS and its deficiency amerliorates disease in mouse models of MS (45, 46) . Also, blockade of IL-6 prevents some aspects of chronic heart transplant rejection in a mouse model after transient depletion of CD4 T cells (47) . While reduced susceptibility to AICD may be pathological in the above settings, it may increase the protective potential of CD8 T cells during infection and in response to malignancies. In mouse models, CD8 T cells activated in the presence of IL-1β, IL-6, IL-23, IL-21, and TGFβ can mediate protective immunity against influenza infection and some tumors (48, 49) .
In our studies, we have examined the effects of inflammatory cytokines on primary human CD8 T cell death. Inflammatory conditions are known to direct the differentiation of naïve CD4 T cells into effector cells that produce distinct cytokines, such as IFNγ, IL-4, and IL-17A. Although CD8 T cells have been reported to be capable of producing these effector cytokines in some studies, the large majority of human CD8 T cells produce IFNγ after TCR activation and only a very small minority can be induced to express IL-4 or IL-17A (50-52). We have examined the production of IL-17A from human CD8 T cells activated in IL-1/6/23 because of the establishment of these cytokines in facilitating the differentiation of IL-17A-producing CD4 T cells (although TGFβ is also necessary in mouse T cells and perhaps in human T cells) (14, 15, 53) . Consistent with previous reports (52), we observed IL-17A production in less than 0.5% of peripheral blood human CD8 T cells after activation in the presence of IL-1/6/23 (data not shown). It is likely that these IL-17A-producing cells are derived from a small subset of CD161-positive precursors (54, 55) and our findings appear to be unrelated to the very limited differentiation of total human CD8 T cells into IL-17A-expressing effectors.
In summary, we have shown that the nature of inflammatory signals received by human CD8 T cells during TCR stimulation dictates their susceptibility to AICD. Specifically, CD8 T cells activated in the presence of IL-1/6/23 undergo less Fas-mediated AICD than those activated in the presence of IL-12. This is related to lower expression of FasL and is regulated by the expression of c-FLIP. These findings provide important insight into the biology of human effector T cell responses, and have implications for understanding the regulation of CD8 effector T cells. 
